Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as having “best-in-class potential” in a competitive field.

Vertex stock popped late Monday on promising test results for a drug that could treat a chronic autoimmune disease that ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX ® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill received ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Over the past year, shares of Centessa Pharmaceuticals (NASDAQ: CNTA) have significantly outperformed broader equities as the ...

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...

A historic moment in pharmaceuticals will happen next week: an FDA advisory committee is set to review the first-ever CRISPR gene editing-based therapy, Vertex Pharmaceuticals and CRISPR Therapeutics’ ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for controversial ...